Uniwersyteckie Centrum Stomatologii I Medycyny Specjalistycznej Sp. z o.o.

Poznan 19 trials 13 recruiting

19 Registered trials

13 Currently recruiting

Organisation

Uniwersyteckie Centrum Stomatologii I Medycyny Specjalistycznej Sp. z o.o.

Location

Poznan, Poland

Identifier

ORG-100045528

Address

Ul. Marcelinska 42, 60-354, Poland

Departments

Cardiology
Endocrinology, Metabolism, and Internal Diseases
Klinika Endokrynologii, Przemiany Materii i Chorób Wewnętrznych (Endocrinology)
N/A
NA
Poradnia Internistyczn
Poradnia Internistyczna
TBC

Clinical trials at this site (19)

Search interface

A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting

2025-524001-33-00 Graves’ Disease 4 2026-05-22
A Study to Evaluate Atumelnant in Adults with Congenital Adrenal Hyperplasia Recruiting

2024-519579-24-00 Classic Congenital Adrenal Hyperplasia 5 2026-02-26
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe… Recruiting

2024-520209-38-00 Obesity or Overweight 5 2025-09-19
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study Recruiting

2025-522338-30-00 Ulcerative Colitis 4 2026-03-31
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting

2025-522674-36-00 Metabolic Dysfunction-Associated Steatotic Liver Diseas 5 2026-03-24
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting

2025-521381-10-00 Moderately to Severely Active Ulcerative Colitis 5 2025-12-03
A Phase 1/2 Study to Assess AMG 732 in Healthy Subjects and Subjects with Thyroid Eye Disease Recruiting

2024-514110-12-00 Thyroid Eye Disease 7 2025-10-22
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight:… Recruiting

2024-520210-21-00 Crohn’s Disease 5 2025-09-19
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination wi… Recruiting

2024-519945-31-00 Type 1 Diabetes 5 2025-08-21
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients with Grave’s Disease Recruiting

2024-516020-33-00 Grave’s Disease 4 2025-06-26
A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's… Recruiting

2023-509391-42-00 Chron's Disease 11 2025-06-02
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu… Recruiting

2023-506460-14-00 Chronic kidney disease (CKD) and hypertension. 5 2025-05-07
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn… Ended

2023-506457-38-00 Chronic kidney disease (CKD) and hypertension. 5 2024-06-05
A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati… Ended

2023-504124-26-00 Chronic Kidney Disease and High Proteinuria 5 2024-04-04
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended

2023-509198-22-00 Thyroid Eye Disease (TED) 5 2024-10-21
Extension Study to Assess Batoclimab in Participants with TED. Ended

2024-512650-21-00 Thyroid Eye Disease (TED) 5 2023-12-13
Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease. Ended

2024-512648-45-00 Thyroid Eye Disease (TED) 5 2023-11-30